Advancing the prevention and treatment of HIV in children: priorities for research and development

doi:10.1016/S2352-3018(22)00101-1

Review

. 2022 Sep;9(9):e658-e666.

doi: 10.1016/S2352-3018(22)00101-1. Epub 2022 Jul 18.

Advancing the prevention and treatment of HIV in children: priorities for research and development

Martina Penazzato¹, Claire L Townsend², Nadia A Sam-Agudu³, Theodore D Ruel⁴, Moherndran Archary⁵, Adrie Bekker⁶, Tim R Cressey⁷, Angela Colbers⁸, Nandita Sugandhi⁹, Pablo Rojo¹⁰, Natella Rakhmanina¹¹, Melynda Watkins¹², Lisa Frigati¹³, Irene Mukui¹⁴, Asma Hafiz², Marissa Vicari¹⁵, Edmund V Capparelli¹⁶, Elaine J Abrams¹⁷; PADO-HIV 5 participants

Collaborators, Affiliations

Collaborators

PADO-HIV 5 participants:
Elaine Abrams, Moherndran Archary, Adrie Bekker, Edmund Capparelli, Angela Colbers, Tim Cressey, Lisa Frigati, Asma Hafiz, Irene Mukui, Martina Penazzato, Natella Rakhmanina, Pablo Rojo, Theodore Ruel, Nadia Sam-Agudu, Nandita Sugandhi, Claire Townsend, Marissa Vicari, Melynda Watkins

Affiliations

¹ HIV Department, WHO, Geneva, Switzerland. Electronic address: penazzatom@who.int.
² HIV Department, WHO, Geneva, Switzerland.
³ Pediatric and Adolescent HIV Program and International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria; Institute of Human Virology and Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.
⁴ Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
⁵ Department of Paediatrics, University of KwaZulu-Natal, Durban, South Africa.
⁶ Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
⁷ AMS-IRD Research Collaboration, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
⁸ Department of Pharmacy, Radboud Institute for Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, Netherlands.
⁹ ICAP, Columbia University, New York, NY, USA.
¹⁰ Pediatric Infectious Diseases Unit, Hospital 12 de Octubre, Madrid, Spain.
¹¹ School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA; Children's National Hospital, Washington, DC, USA; Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA.
¹² Clinton Health Access Initiative, Boston, MA, USA.
¹³ Department of Paediatrics, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.
¹⁴ Drugs for Neglected Diseases Initiative, Nairobi, Kenya.
¹⁵ International AIDS Society, Geneva, Switzerland.
¹⁶ Department of Pediatrics and Clinical Pharmacy, University of California San Diego, La Jolla, CA, USA.
¹⁷ ICAP, Columbia University, New York, NY, USA; Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.

PMID: 35863362
DOI: 10.1016/S2352-3018(22)00101-1

Review

Advancing the prevention and treatment of HIV in children: priorities for research and development

Martina Penazzato et al. Lancet HIV. 2022 Sep.

. 2022 Sep;9(9):e658-e666.

doi: 10.1016/S2352-3018(22)00101-1. Epub 2022 Jul 18.

Authors

Collaborators

PADO-HIV 5 participants:
Elaine Abrams, Moherndran Archary, Adrie Bekker, Edmund Capparelli, Angela Colbers, Tim Cressey, Lisa Frigati, Asma Hafiz, Irene Mukui, Martina Penazzato, Natella Rakhmanina, Pablo Rojo, Theodore Ruel, Nadia Sam-Agudu, Nandita Sugandhi, Claire Townsend, Marissa Vicari, Melynda Watkins

Affiliations

¹ HIV Department, WHO, Geneva, Switzerland. Electronic address: penazzatom@who.int.
² HIV Department, WHO, Geneva, Switzerland.
³ Pediatric and Adolescent HIV Program and International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria; Institute of Human Virology and Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.
⁴ Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
⁵ Department of Paediatrics, University of KwaZulu-Natal, Durban, South Africa.
⁶ Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
⁷ AMS-IRD Research Collaboration, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
⁸ Department of Pharmacy, Radboud Institute for Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, Netherlands.
⁹ ICAP, Columbia University, New York, NY, USA.
¹⁰ Pediatric Infectious Diseases Unit, Hospital 12 de Octubre, Madrid, Spain.
¹¹ School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA; Children's National Hospital, Washington, DC, USA; Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA.
¹² Clinton Health Access Initiative, Boston, MA, USA.
¹³ Department of Paediatrics, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.
¹⁴ Drugs for Neglected Diseases Initiative, Nairobi, Kenya.
¹⁵ International AIDS Society, Geneva, Switzerland.
¹⁶ Department of Pediatrics and Clinical Pharmacy, University of California San Diego, La Jolla, CA, USA.
¹⁷ ICAP, Columbia University, New York, NY, USA; Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.

PMID: 35863362
DOI: 10.1016/S2352-3018(22)00101-1

Abstract

Safe and effective paediatric formulations of the most promising antiretroviral drugs are crucial to advance the treatment and prevention of HIV in neonates, infants, children, and adolescents. The WHO Paediatric Drug Optimization for HIV (PADO-HIV) group brings together stakeholders and experts every 2-3 years to identify priority products and define research gaps in the development of new HIV drugs and formulations for children in low-income and middle-income countries. PADO-HIV 5 met from Sept 27 to Oct 15, 2021. The group evaluated HIV agents from known and novel drug classes, oral and parenteral long-acting formulations, and developments in broadly neutralising antibodies, and included focused sessions on neonates and new delivery technologies. A list of medium-term and long-term priorities was generated, and research questions were defined. This forward-looking analysis is intended to provide guidance to funders, drug developers, and researchers, and to accelerate access for children to the best HIV drugs and formulations.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests AC received research grants from Merck, Gilead, and ViiV Healthcare, and a consultancy fee from Merck, all paid to AC's institution. PR received research grants from ViiV and has been on an advisory board for Merck. MV received educational grants from ViiV, Janssen, and MSD. All other authors declare no competing interests.

Cited by

Studies of young adults with perinatal HIV infection provide new clues for HIV cure.
Kuhn L, Thomas P. Kuhn L, et al. AIDS. 2025 Mar 15;39(4):457-458. doi: 10.1097/QAD.0000000000004107. Epub 2025 Feb 27. AIDS. 2025. PMID: 40009204 No abstract available.
Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review.
Townsend CL, O'Rourke J, Milanzi E, Collins IJ, Judd A, Castro H, Vicari M, Jesson J, Leroy V, Renaud F, Penazzato M. Townsend CL, et al. J Int AIDS Soc. 2022 Nov;25(11):e25970. doi: 10.1002/jia2.25970. J Int AIDS Soc. 2022. PMID: 36377082 Free PMC article.
Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review.
O'Rourke J, Townsend CL, Milanzi E, Collins IJ, Castro H, Judd A, Vicari M, Jesson J, Leroy V, Penazzato M, Renaud F. O'Rourke J, et al. J Int AIDS Soc. 2023 Feb;26(2):e26037. doi: 10.1002/jia2.26037. J Int AIDS Soc. 2023. PMID: 36823283 Free PMC article.
Prevention, treatment and cure of HIV infection.
Landovitz RJ, Scott H, Deeks SG. Landovitz RJ, et al. Nat Rev Microbiol. 2023 Oct;21(10):657-670. doi: 10.1038/s41579-023-00914-1. Epub 2023 Jun 21. Nat Rev Microbiol. 2023. PMID: 37344551 Review.
Antiretroviral medications for pediatric use in the context of the Unified Health System: are there therapeutic gaps in Brazil?
Costa SMD, Aguiar PM. Costa SMD, et al. Rev Paul Pediatr. 2025 Aug 4;43:e2024141. doi: 10.1590/1984-0462/2025/43/2024141. eCollection 2025. Rev Paul Pediatr. 2025. PMID: 40767680 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

001/WHO_/World Health Organization/International

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Advancing the prevention and treatment of HIV in children: priorities for research and development

Collaborators

Affiliations

Advancing the prevention and treatment of HIV in children: priorities for research and development

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous